Is Sermorelin Legal in Wisconsin?

The Federal Legal Framework That Governs Sermorelin

Sermorelin sits in a carefully defined federal regulatory space. It is not a DEA Schedule I through V controlled substance, so possession and prescribing are not subject to DEA quotas or Schedule-specific rules. The complexity comes from the FDA's oversight of compounded drug substances, which is where most patients actually obtain it.

What Sermorelin Is, Chemically

Sermorelin is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous growth hormone (GH) secretion. A double-blind trial published in the Journal of Clinical Endocrinology and Metabolism found that sermorelin acetate produced statistically significant increases in GH secretion and IGF-1 in adults with growth hormone deficiency [1]. Because it acts upstream of GH itself, it preserves the normal pulsatile pattern of GH release, which is a pharmacological difference from direct exogenous GH administration [2].

FDA Approval History

Geref (sermorelin acetate) held FDA approval from 1997 through 2008 for the treatment of idiopathic growth hormone deficiency in children. The manufacturer voluntarily withdrew the New Drug Application for business reasons, not because of safety findings [3]. That withdrawal means no currently approved finished drug product containing sermorelin exists on the US market. The absence of an approved product is what forces patients into the compounding channel.

The 503A Compounding Pathway

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug that is not commercially available when a prescriber provides a valid patient-specific prescription [4]. For sermorelin, the 503A route is the primary legal mechanism for adult patients today. A compounding pharmacy using this route must:

• Use active pharmaceutical ingredients (APIs) from an FDA-registered facility
• Compound only on receipt of a valid patient-specific prescription
• Not produce copies of commercially available drugs
• Comply with USP Chapter 797 sterile compounding standards for any injectable preparation [5]

The 2023 Bulk Drug Substance List and Its Effect

In 2023, the FDA issued a proposed rule that would have removed several peptides, including sermorelin, from the list of bulk drug substances that 503A pharmacies may use without further review [6]. The agency's concern was that, without an approved finished drug product, the clinical need had to be affirmatively demonstrated. As of early 2025, this regulatory process remains active. Several compounding pharmacy trade groups submitted comments defending sermorelin's clinical utility for adult GH deficiency, and the FDA has not finalized a categorical ban [7]. Patients and prescribers should verify the current status with their compounding pharmacy before initiating treatment, because this rule could change dispensing availability on relatively short notice.

503B Outsourcing Facilities

503B outsourcing facilities operate under hospital-grade Current Good Manufacturing Practice (cGMP) standards and may produce larger batches without patient-specific prescriptions [8]. Most sermorelin used in clinical practice comes through 503A compounding pharmacies rather than 503B facilities. If you are obtaining sermorelin through a 503B outsourcing facility, confirm the facility is registered with the FDA's outsourcing facility list [9].

Wisconsin-Specific Legal Status

Wisconsin does not have a state statute that independently bans or restricts sermorelin beyond federal rules. The legal analysis at the state level involves three bodies: the Wisconsin Department of Safety and Professional Services (DSPS), the Wisconsin Pharmacy Examining Board, and the Wisconsin Medical Examining Board.

Wisconsin Pharmacy Examining Board Rules

The Wisconsin Pharmacy Examining Board enforces pharmacy practice standards consistent with, but not identical to, federal law. A pharmacy compounding sterile preparations in Wisconsin must hold a valid pharmacy permit and comply with USP 797 standards for sterile compounding, which govern particulate contamination limits, beyond-use dating, and environmental monitoring [5]. Sermorelin injections are sterile preparations, so any Wisconsin compounding pharmacy dispensing them must meet these standards. The Board has not enacted any sermorelin-specific prohibition as of the date of this article.

Wisconsin Medical Examining Board and Prescribing Authority

Prescribers in Wisconsin may prescribe compounded preparations when a commercially available product cannot meet the patient's clinical need, which is exactly the scenario sermorelin occupies given the 2008 market withdrawal. The Wisconsin Medical Practice Act requires that prescribing be based on a legitimate medical purpose arising from a valid patient-provider relationship [10]. A prescription written without any examination, history review, or documented clinical indication would not meet this standard. Wisconsin does allow telehealth encounters to establish this relationship, but the provider must conduct a clinically adequate evaluation before issuing any prescription, including one for sermorelin [11].

No State-Level Scheduling

Wisconsin's Uniform Controlled Substances Act schedules substances in Categories I through V, mirroring federal scheduling with some additions. Sermorelin does not appear on Wisconsin's controlled substance schedules [12]. This means Wisconsin adds no additional prescribing or dispensing barriers beyond what federal law already requires.

Out-of-State Pharmacies Shipping to Wisconsin

Many patients use telehealth platforms that connect them with out-of-state compounding pharmacies. Wisconsin law permits an out-of-state pharmacy to ship to a Wisconsin resident if the pharmacy is licensed to conduct business in Wisconsin or has a valid nonresident pharmacy permit issued by DSPS. Patients should confirm their compounding pharmacy holds the appropriate Wisconsin permit before accepting a shipment. The FDA's guidance on interstate distribution of compounded drugs under 503A applies here as well [4].

Clinical Basis for Prescribing Sermorelin in Adults

A Wisconsin clinician writing a sermorelin prescription must have a legitimate medical rationale. Understanding that rationale helps patients approach the appointment productively and helps clinicians document the prescription correctly.

Adult Growth Hormone Deficiency

The Endocrine Society's 2011 clinical practice guideline defines adult growth hormone deficiency (AGHD) as a specific medical condition warranting treatment, typically in patients with hypothalamic or pituitary disease, or in those with childhood-onset GHD transitioning to adult care [13]. Sermorelin's mechanism of stimulating endogenous GH release makes it a pharmacologically appropriate tool when the pituitary remains capable of responding to GHRH, though it is not a replacement for standard GH therapy in severe verified AGHD under current guidelines.

Age-Related GH Decline

GH secretion declines roughly 14% per decade after age 30, a process sometimes called somatopause [14]. Some clinicians prescribe sermorelin for this physiologic decline in patients who do not meet formal AGHD criteria but who have symptoms such as reduced lean muscle mass, increased central adiposity, impaired sleep, and low IGF-1 for age. This prescribing is off-label. It is not prohibited, but the prescriber must document the clinical reasoning and confirm that compounding pharmacy dispensing in this context satisfies the federal definition of "not commercially available," which sermorelin does satisfy given the market withdrawal [3].

Baseline Labs and Monitoring Protocol

Before prescribing, a responsible Wisconsin clinician will typically obtain:

1. IGF-1 (insulin-like growth factor 1) to establish baseline GH axis activity [13]
2. Fasting glucose and HbA1c, because GH-stimulating agents can cause transient insulin resistance [15]
3. Thyroid function (TSH, free T4), since untreated hypothyroidism blunts the GH response to sermorelin [16]
4. A complete metabolic panel to screen for contraindications

Follow-up IGF-1 at 90 days is standard practice to assess response and adjust dose [13].

How to Get Sermorelin in Wisconsin: A Practical Pathway

Getting sermorelin lawfully in Wisconsin requires moving through a defined sequence of steps. Skipping any step creates legal or clinical risk.

Step 1: Find a Qualified Prescriber

A physician (MD or DO), nurse practitioner, or physician assistant licensed in Wisconsin may prescribe sermorelin. The prescriber should have experience with endocrinology, men's health, women's health, or anti-aging medicine, and must document a legitimate clinical indication. Options include:

• A Wisconsin-licensed endocrinologist or internal medicine specialist
• A telehealth provider who is licensed in Wisconsin and conducts a synchronous video or phone evaluation that meets the Medical Examining Board's telehealth prescribing standards [11]
• A direct primary care or concierge medicine practice with compounding experience

Step 2: Complete a Clinical Evaluation

The evaluation must include a medical history, review of current medications, symptom assessment, and baseline laboratory work (IGF-1, fasting glucose, thyroid function at minimum). The prescriber must determine that sermorelin is appropriate and that a compounded product is necessary because no commercially available equivalent exists.

Step 3: Obtain a Patient-Specific Prescription

The prescription must be written for a specific patient, not a standing or batch order. It should specify the concentration (commonly 5 mg/mL to 9 mg/mL reconstituted in bacteriostatic water), the dose in milligrams, the route (subcutaneous injection), and the frequency (typically 5 nights per week before sleep to align with the natural nocturnal GH pulse [17]).

Step 4: Use a Compliant Compounding Pharmacy

The compounding pharmacy must:

• Hold a valid Wisconsin pharmacy permit or nonresident pharmacy permit
• Source sermorelin API from an FDA-registered facility
• Compound under USP 797 sterile conditions [5]
• Verify its current legal ability to compound sermorelin given the ongoing FDA bulk drug substance review [6]

Patients should ask their pharmacy to confirm in writing that it sources API from an FDA-registered supplier and that it has reviewed the current regulatory status of sermorelin under the 503A bulk substances list.

Step 5: Follow Up and Monitor

IGF-1 should be rechecked at 3 months. If IGF-1 has not risen toward mid-normal range for age and sex, the prescriber may adjust the dose or evaluate for confounding factors (hypothyroidism, obesity, poor sleep, concurrent corticosteroid use) that blunt GH response [13]. Glucose should be monitored in patients with prediabetes or risk factors for type 2 diabetes, because GH-axis stimulation can reduce insulin sensitivity [15].

Sermorelin Versus Direct Growth Hormone: Why the Distinction Matters Legally

Recombinant human growth hormone (rhGH, somatropin) is a Schedule-adjacent substance in the sense that federal law (21 USC 333e) specifically restricts its distribution to treatment of a disease or recognized medical condition [18]. Off-label prescribing of rhGH for anti-aging purposes is a federal crime for the prescriber and the dispenser, not just a regulatory issue. Sermorelin does not carry that specific federal restriction. It stimulates the body's own GH production rather than replacing it exogenously, and the 21 USC 333e prohibition on off-label GH distribution does not apply to it. This is a meaningful legal difference that makes sermorelin the preferred option when a clinician wants to support GH axis function outside of diagnosed AGHD.

A review article in Endocrine Practice noted that GHRH analogs like sermorelin "offer a physiologically plausible approach to supporting GH axis function with a different regulatory and safety profile than exogenous somatropin" [19]. That distinction is not merely academic. It determines what a Wisconsin prescriber can legally offer without running into the federal statute that criminalizes off-label somatropin prescribing.

Safety Profile and Contraindications Relevant to Wisconsin Prescribers

No medication is without risk. Sermorelin's adverse event profile is generally mild but must be reviewed before prescribing.

Common Adverse Effects

The most frequently reported effects from the original Geref NDA data include injection site reactions (redness, swelling, pain), facial flushing, headache, and transient dizziness [3]. These typically resolve without intervention.

Contraindications

The FDA's guidance based on Geref labeling identifies the following contraindications or warnings [3]:

• Active malignancy (GH axis stimulation may promote tumor growth in susceptible individuals)
• Pregnancy (insufficient data; avoid)
• Untreated hypothyroidism (blunts response and may worsen metabolic status)
• Known hypersensitivity to sermorelin or any component of the formulation

Drug Interactions

Glucocorticoids reduce GH secretion and may blunt the response to sermorelin [16]. Patients on chronic corticosteroid therapy should have this interaction documented and monitored. Insulin and oral hypoglycemic agents may require dose adjustment if GH-mediated insulin resistance develops [15].

Long-Term Safety Data Gaps

Geref's approval was in pediatric patients. Long-term controlled safety data in adults are limited. A 6-month double-blind trial by Vittone et al. (N=89) found sermorelin safe and well tolerated in older adults, with no serious adverse events attributed to the drug [20]. Prescribers should counsel patients that extended use beyond 6 months lacks the depth of long-term safety evidence that exists for drugs with large Phase III trial programs.

Telehealth and Sermorelin in Wisconsin

Wisconsin's telehealth statute (Wis. Stat. § 448.9748) allows licensed providers to establish a patient-provider relationship via synchronous audio-video technology [11]. This means a Wisconsin resident does not need to travel to a clinic to obtain a sermorelin prescription, provided the telehealth encounter meets the following conditions:

1. The provider holds a current Wisconsin license in the relevant discipline
2. The encounter includes a medical history, symptom review, and review of laboratory results
3. The prescription is clinically indicated and documented in a medical record

Several national telehealth platforms that specialize in hormone optimization operate in Wisconsin and can prescribe sermorelin through this mechanism. Patients should confirm that the prescribing provider (not just the platform) holds a current Wisconsin license. The Wisconsin Medical Examining Board has authority to discipline a licensee for prescribing without adequate clinical basis, regardless of the delivery modality [10].

What "Gray Area" Means and Where Sermorelin Stands

The phrase "gray area" is used loosely in online discussions of peptide therapy. For sermorelin, the genuine regulatory uncertainty is the FDA's ongoing bulk drug substance rulemaking [6], not any ambiguity about scheduling or state-level prohibition. As of January 2025:

• Sermorelin is not a controlled substance at the federal or Wisconsin state level [12]
• Sermorelin may be compounded under 503A with a valid patient-specific prescription [4]
• The FDA has proposed removing it from the 503A bulk list, but that rule is not final [6]
• No Wisconsin state law specifically restricts sermorelin beyond federal requirements

The practical risk for patients is not arrest or prosecution. The risk is that a regulatory change could limit the ability of 503A pharmacies to compound it. Patients and prescribers should monitor the FDA's docket (Docket No. FDA-2019-N-5043) for updates [7].